How Fast Does Aortic Valve Stenosis Progress: The Lipoprotein(a) Factor

At the Kahn Center, we see many patients for evaluation of their coronary heart disease (CHD) and aortic valve stenosis (AVS) from a calcified valve. For over a decade, a routine lab test has been to measure Lipoprotein( a) or Lp(a) in all patients. Lp(a) is an important inherited factor in both CHD and AVS.

Unfortunately, as of now, there are currently no lifestyle or pharmacological treatments available to slow hemodynamic progression of AVS so we just watch it over time and intervene with surgical or catheter valve replace called TAVR when it is severe.

Plasma Lp(a) concentrations predict AVS but its association with hemodynamic progression is controversial. A new study provides information on this important topic.

STUDY
The study included patients with aortic stenosis from 5 longitudinal clinical studies conducted from March 2001 to March 2023 in Canada and the UK. Of 757 total patients, data on plasma lipoprotein(a) concentrations and rates of hemodynamic progression assessed by echocardiography were available for 710, who were included in this analysis. Data were analyzed from March 2023 to April 2024.

MEASUREMENTS
Hemodynamic aortic stenosis progression on echocardiography as assessed by annualized change in peak aortic jet velocity, mean transvalvular gradient, and aortic valve area.

RESULTS

Among the included patients, 497 (70%) were male and 213 (30%) were female. The mean age was 65 years.

Patients in the top lipoprotein(a) tertile demonstrated 41% faster progression of peak aortic jet velocity and 57% faster progression of mean transvalvular gradient than patients in the bottom tertile, both measures of echocardiography of the severity of the AVS.

CONCLUSIONS

In this study, higher plasma lipoprotein(a) concentrations were associated with faster rates of hemodynamic progression in patients with AVS.

What is unknown is whether lowering plasma Lp(a) concentrations wiil impact the progression of AVS. Prior studies with vitamin K2 and statins did not show a slowing of AVS over time. The ongoing trials of new agents to lower Lp(a) may give some data on this important topic.

At the Kahn Center, we do work with patients to lower their Lp(a) and have been quite successful using a multitude of approaches.

Author

Dr. Joel Kahn

You Might Also Enjoy...

Why You Want to Add GG to Your Statin Prescription

GG supplementation boosts the synthesis of essential cell signaling molecules not achieved by CoQ10 supplementation. GG supplementation mitigates many of the side effects of statins, which affect mitochondrial function and cellular health.

Heart Disease in Women: A Little Bit Goes Far for Harm

In women, major adverse cardiovascular events appeared to emerge at a lower PB, and to rise more sharply. Findings support sex-specific interpretation of coronary computed tomography angiography-derived plaque metrics for timely intervention in women.

Do Children Raised on a Vegan Diet Have Acceptable Growth Patterns?

These findings suggest that family vegan dietary patterns may support appropriate infant growth, but further work is needed to clarify how vegan diet quality and nutritional counseling during pregnancy and infancy support optimal infant development.

Ezetimibe (Zetia) May Lower the Risk of Dementia Sevenfold!

The animal and cultured-cell models for which we present data substantiate that ezetimibe indeed reduces aggregates across a broad spectrum of biological systems, and that it does so by blocking or dissociating dysfunctional (or non-functional) interaction

What Do Medical Societies Worldwide Advise for Saturated Fat Intake?

The official positions of WHO, AHA, ESC and most national cardiology and heart foundations still recommend keeping saturated fat ≤10% of energy for the general population and closer to 5–7% for those at elevated cardiovascular risk.

What Do Cardiologists Say About the New Food Pyramid? Eat Plants

Plant-forward eating patterns remain the most consistent dietary strategy for reducing cardiovascular risk. Clinicians should use simple tools and knowledge to proactively translate the DGA into clear, evidence-based guidance for patients.